Marksans Pharma Limited — PPTs, 11-02-2025: Investor Presentation

**Financial Highlights:**

In Q3 FY25, Marksans Pharma reported an operating revenue of ₹682 cr, marking a 16.3% year-over-year growth. The US market drove this surge with a notable 37% increase in revenue. Gross profit jumped to ₹384 cr, reflecting a gross margin expansion of 279 bps to 56.2%, aided by better product mix and lower raw material costs. However, EBITDA was ₹139 cr, up 4.3% YoY, with a reported EBITDA margin of 20.4%, down 234 bps due to increased expenses related to the new facility and freight costs. PAT reached an all-time high of ₹105 cr, with a net margin improvement to 14.8%.

**Strategic Initiatives and Growth Drivers:**

Marksans aims to capitalize on the growing OTC market, projected to reach $204 billion by 2025. The company plans to significantly enhance capacity at its newly acquired TEVA facility to 8 billion units per annum, with the initial phase expected to complete by FY25. An active product pipeline and recent FDA approvals reflect a robust R&D strategy, with continued focus on launching a diverse range of products catering to key therapeutic segments.

**Business Developments:**

Marksans continues to strengthen its market position through strategic acquisitions and expansion efforts. The company has been successfully integrating its recent acquisitions to enhance operational capabilities and market reach while focusing on product expansion in the US and UK markets.

**Market Position and Competitive Advantage:**

With a diversified portfolio servicing major international markets, Marksans ranks among the top Indian pharmaceutical firms, particularly in the OTC segment. Its commitment to sustainable growth through disciplined capital allocation and strategic initiatives positions it well for future expansion.

**Investor Implications:**

Overall, Marksans’ strong quarterly performance, along with its aggressive growth strategy and healthy financials, presents a positive outlook for investors. The company's strong cash position and ambitious plans to double revenue in the US over the next two years add to the potential for significant returns. Investors are encouraged to monitor Marksans closely for future developments and opportunities.